Bolli GB, Landgraf W, Bosnyak Z, et al. - Researchers intended to determine if there is an association between baseline fasting C‐peptide (FCP) and glucose control in insulin‐naive people with type 2 diabetes mellitus (T2DM) inadequately controlled with oral anti‐hyperglycaemic drugs starting basal insulin glargine 300 U/mL (Gla‐300) or 100 U/mL (Gla‐100) in the absence of sulfonylurea/glinides. Candidates with FCP measurement from the EDITION 3 trial (n = 867) were stratified by baseline FCP (≤ 0.40, > 0.40–1.20, > 1.20 nmol/L); 11.0%, 70.9%, and 18.1% contributed to each group. For all definitions (time periods and levels) of hypoglycaemia, more people with lower baseline FCP reported hypoglycaemia with both insulins, but with numerically lower incidence for Gla‐300 vs Gla‐100 across all FCP groups. This indicates that Gla‐300 may be particularly beneficial for those at higher risk of hypoglycaemia.